Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu
Trial record 1 of 1 for:    NCT00514891
Previous Study | Return to List | Next Study

Impact of the WHO Recommended Vitamin A Supplementation at Immunisation Contacts

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00514891
Recruitment Status : Terminated (Reccomended by DSMB after review of planned interim analyses.)
First Posted : August 10, 2007
Last Update Posted : March 1, 2011
Ministry of Health, Guinea-Bissau
University of Aarhus
Information provided by:
Bandim Health Project

Brief Summary:

High-dose vitamin A to children above 6 months of age reduces all-cause mortality by 23-30%. The WHO recommends vitamin A supplementation (VAS) with the first vaccine after 6 months of age. However, the effect of providing VAS with vaccines has never been investigated. We have hypothesised that the effect of VAS depends on the immune stimulus at the time of supplementation. Hence, the effect might vary depending on which type of vaccine it is given with. In particular, we hypothesised that VAS might be beneficial when given with measles vaccine but not when given with DTP vaccine. Normally the first vaccine after 6 months of age would be a measles vaccine, but many children come late for their DTP vaccinations and receive DTP alone or together with measles vaccine. Hence, it is important to study whether the effect of VAS is the same irrespective of the vaccine(s) administered at the same time.

Guinea-Bissau has not yet implemented the WHO vitamin A policy of providing VAS with vaccines, but plans to do so within the next years. Together with the Ministry of Health in Guinea-Bissau, the Bandim Health Project (BHP) in Guinea-Bissau will investigate the effect on mortality and morbidity of implementing the WHO vitamin A policy in Guinea-Bissau. This will be done in a large randomised trial.

BHP has a demographic surveillance system (DSS) which has followed a population of now more than 150,000 individuals for almost 30 years. Children will be randomised to receive VAS or placebo with their first vaccine after 6 months of age, and will be followed through the DSS to assess mortality and morbidity. Based on previous observations, the effects of VAS might differ according to sex and season. The interaction between VAS, sex, and season will also be studied in the present trial. By identifying situations where VAS may be beneficial, ineffective, or even harmful the study may contribute importantly to optimising the VAS policy for low-income countries.

Condition or disease Intervention/treatment Phase
Mortality Morbidity Biological: Vitamin A Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 9500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Evaluation of the Impact on Mortality and Morbidity of the WHO Recommended Vitamin A Supplementation at First Immunisation Contact After 6 Months of Age
Study Start Date : August 2007
Estimated Primary Completion Date : June 2012
Estimated Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Vitamin A

Arm Intervention/treatment
Active Comparator: 1
Vitamin A supplementation
Biological: Vitamin A
The effect of vitamin A given with different vaccines will be studied

Placebo Comparator: 2
Biological: Vitamin A
The effect of vitamin A given with different vaccines will be studied

Primary Outcome Measures :
  1. Mortality, morbidity [ Time Frame: 1 year ]

Secondary Outcome Measures :
  1. Growth, Vitamin A status, Immunology

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Months to 23 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Urban area: 6-17-month-old children, presenting for vaccination at a health centre in the study area.
  • Rural area: 6-23-month-old children who are missing one or more routine vaccinations when visited by our mobile team.

Exclusion Criteria:

  • Normally applied contraindications for receiving vaccinations, including high fever.
  • VAS within last month.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00514891

Layout table for location information
Bandim Health Project, Apartado 861
Bissau, Guinea-Bissau
Sponsors and Collaborators
Bandim Health Project
Ministry of Health, Guinea-Bissau
University of Aarhus
Layout table for investigator information
Principal Investigator: Christine S Benn, MD, PhD Bandim Health Project, Statens Serum Institut, Artillerivej 5, 2300 Copenhagen S, Denmark
Study Director: Peter Aaby, Dr.Med. Bandim Health Project, Apartado 861, 1004 Bissau Codex, Guinea-Bissau

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Ane Fisker, Bandim Health Project Identifier: NCT00514891    
Other Study ID Numbers: CVK-2006-7041-99
First Posted: August 10, 2007    Key Record Dates
Last Update Posted: March 1, 2011
Last Verified: January 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Vitamin A
Retinol palmitate
Growth Substances
Physiological Effects of Drugs
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Protective Agents
Anticarcinogenic Agents
Antineoplastic Agents